|
1
|
McMaster ML, Goldstein AM, Bromley CM,
Ishibe N and Parry DM: Chordoma: Incidence and survival patterns in
the United States, 1973–1995. Cancer Causes Control. 12:1–11. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hung GY, Horng JL, Yen HJ, Yen CC, Chen
WM, Chen PC, Wu HT and Chiou HJ: Incidence Patterns of Primary Bone
Cancer in Taiwan (2003–2010): A Population-Based Study. Ann Surg
Oncol. 21:2490–2498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee J, Bhatia NN, Hoang BH, Ziogas A and
Zell JA: Analysis of prognostic factors for patients with chordoma
with use of the California Cancer Registry. J Bone Joint Surg Am.
94:356–363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu Z, Zhang J, Zhang L, Jia G, Tang J,
Wang L and Wang Z: Prognostic factors for long-term outcome of
patients with surgical resection of skull base chordomas-106 cases
review in one institution. Neurosurg Rev. 33:451–456. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Maio S, Rostomily R and Sekhar LN:
Current surgical outcomes for cranial base chordomas: Cohort study
of 95 patients. Neurosurgery. 70:1355–1360. 2010. View Article : Google Scholar
|
|
6
|
Di Maio S, Temkin N, Ramanathan D and
Sekhar LN: Current comprehensive management of cranial base
chordomas: 10-year meta-analysis of observational studies. J
Neurosurg. 115:1094–1105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vujovic S, Henderson S, Presmeau N, Odell
E, Jacques TS, Tirabosco R, Boshoff C and Flanagan AM: Brachyury, a
crucial regulator of notochordal development, is a novel biomarker
for chordomas. J Pathol. 209:157–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Presneau N, Shalaby A, Ye H, Pillay N,
Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG,
et al: Role of the transcription factor T (brachyury) in the
pathogenesis of sporadic chordoma: A genetic and function-based
study. J Pathol. 223:327–335. 2011. View Article : Google Scholar
|
|
9
|
Yang XR, Ng D, Alcorta DA, Liebsch NJ,
Sheridan E, Li S, Goldstein AM, Parry DM and Kelley MJ: T
(brachyury) gene duplication confers major susceptibility to
familial chordoma. Nat Genet. 41:1176–1178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pillay N, Plagnol V, Tarpey PS, Lobo SB,
Presneau N, Szuhai K, Halai D, Berisha F, Cannon SR, Mead S, et al:
A common single-nucleotide variant in T is strongly associated with
chordoma. Nat Genet. 44:1185–1187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Z, Wang K, Wang L, Feng J, Hao S, Tian
K, Zhang L, Jia G, Wan H and Zhang J: The brachyury Gly177Asp SNP
is not associated with a risk of skull base chordoma in Han Chinese
population. Int J Mol Sci. 14:21258–21265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jambhekar NA, Rekhi B, Thorat K, Dikshit
R, Agrawal M and Puri A: Revisiting chordoma with brachyury, a 'New
Age' marker-Analysis of a validation study on 51 cases. Arch Pathol
Lab Med. 134:1181–1187. 2010.PubMed/NCBI
|
|
13
|
Zhang L, Guo S, Schwab JH, Nielsen GP,
Choy E, Ye S, Zhang Z, Mankin H, Hornicek FJ and Duan Z: Tissue
microarray immunohistochemical detection of brachyury is not a
prognostic indicator in chordoma. PLoS One. 8:e758512013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi D, Melcher R, Harms J and Crockard A:
Outcome of 132 operations in 97 patients with chordomas of the
craniocervical junction and upper cervical spine. Neurosurgery.
66:59–65. 2010. View Article : Google Scholar
|
|
15
|
Tirabosco R, Mangham DC, Rosenberg AE,
Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di
Francesco L, Kalil RK, et al: Brachyury expression in extra-axial
skeletal and soft tissue chordomas: A marker that distinguishes
chordoma from mixed tumor/myoepithelioma/parachordoma in soft
tissue. Am J Surg Pathol. 32:572–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Palena C, Fernando RI and Hamilton DH: An
immunotherapeutic intervention against tumor progression: Targeting
a driver of the epithelial-to-mesenchymal transition.
Oncoimmunology. 3:e272202014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roselli M, Fernando RI, Guadagni F, Spila
A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M,
Hamilton D, Huang B, et al: Brachyury, a driver of the
epithelial-mesenchymal transition, is overexpressed in human
lungtumors: An opportunity for novel interventions against lung
cancer. Clin Cancer Res. 18:3868–3879. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kilic N, Feldhaus S, Kilic E, Tennstedt P,
Wicklein D, Wasielewski RV, Viebahn C, Kreipe H and Schumacher U:
Brachyury expression predicts poor prognosis at early stages of
colorectal cancer. Eur J Cancer. 47:1080–1085. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kitamura Y, Sasaki H, Kimura T, Miwa T,
Takahashi S, Kawase T and Yoshida K: Molecular and clinical risk
factors for recurrence of skull base chordomas: Gain on chromosome
2p, expression of brachyury and lack of irradiation negatively
correlate with patient prognosis. J Neuropathol Exp Neurol.
72:816–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen J, Li CD, Yang HL, Lu J, Zou TM, Wang
DL and Deng M: Classic chordoma coexisting with benign notochordal
cell rest demonstrating different immunohistological expression
patterns of brachyury and galectin-3. J Clin Neurosci. 18:96–99.
2011. View Article : Google Scholar
|
|
21
|
Le LP, Nielsen GP, Rosenberg AE, Thomas D,
Batten JM, Deshpande V, Schwab J, Duan Z, Xavier RJ, Hornicek F and
Iafrate AJ: Recurrent chromosomal copy number alterations in
sporadic chordomas. PLoS One. 6:e188462011. View Article : Google Scholar : PubMed/NCBI
|
